Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | alpha/beta hydrolase, putative | 0.0249 | 0.0537 | 0.5 |
Trypanosoma brucei | lipase domain protein, putative | 0.131 | 0.3725 | 1 |
Brugia malayi | Lipase family protein | 0.131 | 0.3725 | 1 |
Chlamydia trachomatis | lysophospholipase esterase | 0.007 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.131 | 0.3725 | 1 |
Echinococcus multilocularis | sn1 specific diacylglycerol lipase beta | 0.131 | 0.3725 | 1 |
Wolbachia endosymbiont of Brugia malayi | esterase | 0.007 | 0 | 0.5 |
Trypanosoma cruzi | Alpha/beta hydrolase family, putative | 0.0198 | 0.0384 | 0.1031 |
Trypanosoma cruzi | Alpha/beta hydrolase family, putative | 0.0198 | 0.0384 | 0.1031 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.131 | 0.3725 | 1 |
Echinococcus granulosus | sn1 specific diacylglycerol lipase beta | 0.131 | 0.3725 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.131 | 0.3725 | 1 |
Loa Loa (eye worm) | lipase | 0.131 | 0.3725 | 1 |
Trypanosoma brucei | lipase domain protein, putative | 0.131 | 0.3725 | 1 |
Echinococcus multilocularis | abhydrolase domain containing protein 11 | 0.0249 | 0.0537 | 0.1441 |
Schistosoma mansoni | family S33 non-peptidase homologue (S33 family) | 0.0249 | 0.0537 | 1 |
Trichomonas vaginalis | lipase containing protein, putative | 0.131 | 0.3725 | 0.5 |
Brugia malayi | hydrolase, alpha/beta fold family protein | 0.0198 | 0.0384 | 0.1031 |
Trichomonas vaginalis | lipase containing protein, putative | 0.131 | 0.3725 | 0.5 |
Onchocerca volvulus | 0.131 | 0.3725 | 0.5 | |
Echinococcus granulosus | abhydrolase domain containing protein 11 | 0.0249 | 0.0537 | 0.1441 |
Toxoplasma gondii | hydrolase, alpha/beta fold family protein | 0.0198 | 0.0384 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0249 | 0.0537 | 0.1441 |
Mycobacterium tuberculosis | Possible hydrolase | 0.0198 | 0.0384 | 0.0382 |
Trypanosoma brucei | Alpha/beta hydrolase family, putative | 0.0198 | 0.0384 | 0.1031 |
Plasmodium falciparum | alpha/beta hydrolase, putative | 0.0249 | 0.0537 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0198 | 0.0384 | 0.1031 |
Mycobacterium tuberculosis | 4,9-DHSA hydrolase | 0.3337 | 0.9813 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 0.631 um | PUBCHEM_BIOASSAY: qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 9.285 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PubChem BioAssay. Inhibitors of USP1/UAF1: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | ||
Saccharomyces cerevisiae | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.